Daiichi Sankyo Condemns Falsely-represented Product - Pharmaceutical Technology

Latest Issue
PharmTech

Latest Issue
PharmTech Europe

Daiichi Sankyo Condemns Falsely-represented Product


ePT--the Electronic Newsletter of Pharmaceutical Technology

Daiichi Sankyo warned that a product being sold online to consumers in Malaysia and Indonesia is illegally using Daiichi Sankyo’s name, logo, and registered trademark and is not manufactured or sold by any Daiichi Sankyo Group companies or subcontractors. The package of the falsely represented product, Glutax 4G Premium, is similar to one of Daiichi Sankyo’s Asian prescription-drug products, the company reported. Daiichi Sankyo placed advertisements in Malaysian and Indonesian consumer publications to warn consumers of the deceit.

Daiichi Sankyo said that the advertisements were published because protecting consumers is its highest priority. The advertisements were published in Malaysian newspapers at the end of January and in February magazine issues, as well as in Indonesian newspapers at the end of February and in March or April magazine issues. The company is preparing to take legal action and is consulting with Malaysian authorities, the company announced in a March 5, 2013 press release.

ADVERTISEMENT

blog comments powered by Disqus
LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
|Monthly
| Weekly

Survey
What role should the US government play in the current Ebola outbreak?
Finance development of drugs to treat/prevent disease.
Oversee medical treatment of patients in the US.
Provide treatment for patients globally.
All of the above.
No government involvement in patient treatment or drug development.
Finance development of drugs to treat/prevent disease.
23%
Oversee medical treatment of patients in the US.
14%
Provide treatment for patients globally.
7%
All of the above.
47%
No government involvement in patient treatment or drug development.
9%
Jim Miller Outsourcing Outlook Jim MillerOutside Looking In
Cynthia Challener, PhD Ingredients Insider Cynthia ChallenerAdvances in Large-Scale Heterocyclic Synthesis
Jill Wechsler Regulatory Watch Jill Wechsler New Era for Generic Drugs
Sean Milmo European Regulatory WatchSean MilmoTackling Drug Shortages
New Congress to Tackle Health Reform, Biomedical Innovation, Tax Policy
Combination Products Challenge Biopharma Manufacturers
Seven Steps to Solving Tabletting and Tooling ProblemsStep 1: Clean
Legislators Urge Added Incentives for Ebola Drug Development
FDA Reorganization to Promote Drug Quality
Source: ePT--the Electronic Newsletter of Pharmaceutical Technology,
Click here